logo
Select company
Select metric
$ -196.26MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
4
Sector
9
Industry
12
History
3
$ 26.83Close
$ 15.13 - $ 28.76 52-Week Range
Ticker Information

Ticker

CLDX

Company Name

CELLDEX THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

CELLDEX THERAPEUTICS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

CLDX - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 3.35M$ -199.61M$ -196.26M
3/31/2025$ 3.27M$ -178.85M$ -175.58M
12/31/2024$ 3.18M$ -157.86M$ -154.69M
9/30/2024$ 3.12M$ -154.08M$ -150.96M
6/30/2024$ 3.1M$ -150.22M$ -147.12M
3/31/2024$ 3.06M$ -144.88M$ -141.82M
12/31/2023$ 3.01M$ -141.43M$ -138.42M
9/30/2023$ 2.92M$ -124.61M$ -121.69M
6/30/2023$ 2.83M$ -113.13M$ -110.31M
3/31/2023$ 2.81M$ -118.64M$ -115.83M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • CELLDEX THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDA stands at $ -44.24M.
  • Over the past 5 years, CELLDEX THERAPEUTICS INC's average EBITDA has been $ -110.02M.
  • The median EBITDA for CELLDEX THERAPEUTICS INC during this period was $ -109.87M
  • CELLDEX THERAPEUTICS INC reached its highest EBITDA over the past 5 years at $ -44.24M.
  • The lowest EBITDA recorded by CELLDEX THERAPEUTICS INC in the same timeframe $ -196.26M

CELLDEX THERAPEUTICS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
LENZ : LENZ THERAPEUTICS INC $ -51.81MPRAX : PRAXIS PRECISION MEDICINES INC $ -249.79MIDYA : IDEAYA BIOSCIENCES INC $ -327.78MDNTH : DIANTHUS THERAPEUTICS INC $ -114.33MPRME : PRIME MEDICINE INC $ -183.24MTSHA : TAYSHA GENE THERAPIES INC $ -90.23MPGEN : PRECIGEN INC $ -121.97MUPB : UPSTREAM BIO INC $ -103.91MVRDN : VIRIDIAN THERAPEUTICS INC $ -340.63MJANX : JANUX THERAPEUTICS INC $ -103.56M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for CELLDEX THERAPEUTICS INC is calculated as follows: EBIT [ $ -48.55M ] + DepAmor [ $ 4.32M ]
(=) EBITDA [ $ -44.24M ]

CLDX - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -196.26M

Minimum

Jun 30, 2025

$ -44.24M

Maximum

Sep 30, 2020

$ -110.02M

Average

$ -109.87M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M